You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Moodys
Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 10,253,102

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,253,102
Title:Antigen-binding proteins that activate the leptin receptor
Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
Inventor(s): Gromada; Jesper (Scarsdale, NY), Stevis; Panayiotis (West Orange, NJ), Altarejos; Judith (Chappaqua, NY)
Assignee: REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:16/007,848
Patent Claims:see list of patent claims

Details for Patent 10,253,102

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Llc TANZEUM albiglutide INJECTABLE;INJECTION 125431 001 2014-04-15   Start Trial REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) 2035-10-12 RX search
Eli Lilly And Co TRULICITY dulaglutide INJECTABLE;INJECTION 125469 001 2015-03-09   Start Trial REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) 2035-10-12 RX search
Eli Lilly And Co TRULICITY dulaglutide INJECTABLE;INJECTION 125469 002 2015-03-09   Start Trial REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) 2035-10-12 RX search
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) 2035-10-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
McKinsey
Baxter
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.